^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LDH-H

    i
    Other names: LDHA, Lactate dehydrogenase A, LDHB, L-lactate dehydrogenase B chain, LDH heart subunit, LDH-H, Renal carcinoma antigen NY-REN-46, Testicular secretory protein Li 25, Epididymis secretory protein Li 281, Lactate dehydrogenase H chain, TRG-5, HEL-S-281
    Entrez ID:
    3939; 3945
    Related biomarkers:
    Expression
    Others
    Associations

    News

    Trials
    over2years
    Effects of Gene Polymorphisms, Metabolic Activity, and Content of Alcohol Dehydrogenase and Acetaldehyde Dehydrogenases on Prognosis of Hepatocellular Carcinoma Patients. (PubMed, Turk J Gastroenterol)
    Low activity of acetaldehyde dehydrogenases in livers correlates with poor prognosis and clinical progression in hepatocel- lular carcinoma patients, and both gene polymorphisms and content influence its metabolic activity.
    Journal
    |
    ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • ADH1C (Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide)
    |
    LDH-L • ADH1C mutation • LDH-H
    over2years
    CLINICAL APPLICABILITY OF TARGETED NEXT-GENERATION SEQUENCING FOR PRECISION MEDICINE IN DIFFUSE LARGE B CELL LYMPHOMA (EHA 2022)
    Ibrutinib, as a single agent, has demonstrated limited activity in DLBCL with mutant MYD88 and wildtype CD79 . In this study, we identified 3 patients with mutant MYD88 and wildtype CD79A/B (8.1%), among whom 2 harbored MYD88 L265P variants and 1 had MYD88 S219C mutation. Conclusion The utility of mutational profiling may facilitate the identification of potential drug targets, which in turns may represent new therapeutic possibilities.
    Clinical • Next-generation sequencing
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • DNMT3A (DNA methyltransferase 1) • ARID1A (AT-rich interaction domain 1A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • CARD11 (Caspase Recruitment Domain Family Member 11) • EP300 (E1A binding protein p300) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4) • TYK2 (Tyrosine Kinase 2)
    |
    TP53 mutation • ARID1A mutation • RUNX1 mutation • MYD88 mutation • LRP1B mutation • MYD88 L265P • LDH-L • NOTCH2 mutation • MYD88 wild-type • LDH-H
    |
    Imbruvica (ibrutinib)
    3years
    The prognostic value of preoperative serum lactate dehydrogenase levels in patients underwent curative-intent hepatectomy for colorectal liver metastases: A two-center cohort study. (PubMed, Cancer Med)
    Our study implicates serum LDH as a reliable and independent laboratory biomarker to predict the clinical outcome of curative-intent surgery for CRLM. Composite of LDH and Fong score is a potential stratification tool for CRLM resection. Prospective, international studies are needed to validate these results across diverse populations.
    Clinical • Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    LDH elevation • LDH-H
    over3years
    Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. (PubMed, Cancers (Basel))
    The ctDNA dynamics outperformed LDH and S100 dynamics. These results confirm the clinical validity of ctDNA measurements as a minimally invasive biomarker for the diagnostic and monitoring trajectory of patients with LDH-high stage IV melanoma.
    Clinical • Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600 • LDH-H
    4years
    The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer. (PubMed, Cancer Immunol Immunother)
    In conclusion, PGE2 produced by MDSC increases the stem cell-like properties and tumor PD-L1 expression in epithelial ovarian cancer. Depleting MDSC may be therapeutically effective against ovarian cancer by reducing the number of CSC and tumor PD-L1 expression.
    Journal • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1)
    |
    PD-L1 expression • PD-L1 overexpression • LDH-H
    |
    QTORIN 3.9% (rapamycin topical)
    over4years
    Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. (PubMed, Cells)
    Furthermore, FGFR1 and PARP expression was upregulated in FGFR1 inhibitor (dasatinib)-resistant PDAC cell lines SU8686, MiaPaCa2, and PANC-1 compared with that in sensitive cell lines Panc0403, Panc0504, Panc1005, and SUIT-2. In conclusion, FGFR1 inhibitor-resistant PDAC cells exhibited sensitivity to PD173074 after olaparib-mediated loss of PARP signaling. The present FGFR1/PARP-mediated synthetic lethality proof-of-concept study provided preclinical evidence of the feasibility and therapeutic efficacy of combinatorial FGFR1/PARP1 inhibition in human PDAC cell lines.
    Clinical • Journal • PARP Biomarker
    |
    FGFR1 (Fibroblast growth factor receptor 1) • BCL2L1 (BCL2-like 1) • RAD51 (RAD51 Homolog A) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
    |
    FGFR1 expression • PARP1 overexpression • LDH-H
    |
    Lynparza (olaparib) • dasatinib